Anti-VEGF agents have been in the market for the past 20 years and show significant efficacy in the treatment of neovascular age-related macular degeneration (nAMD); however, some studies show that half of the patients are unresponsive to them. The gene discussed is VEGFA; the disease is wet macular degeneration.